| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |